Tsai Capital Corp Takes Position in Danaher Corporation $DHR

Tsai Capital Corp acquired a new position in Danaher Corporation (NYSE:DHR) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 9,540 shares of the conglomerate’s stock, valued at approximately $1,885,000. Danaher accounts for approximately 1.4% of Tsai Capital Corp’s investment portfolio, making the stock its 25th largest position.

Several other hedge funds have also recently added to or reduced their stakes in DHR. Red Tortoise LLC lifted its holdings in shares of Danaher by 175.0% during the second quarter. Red Tortoise LLC now owns 154 shares of the conglomerate’s stock worth $30,000 after buying an additional 98 shares during the last quarter. Ramirez Asset Management Inc. acquired a new position in Danaher during the 2nd quarter valued at $40,000. Costello Asset Management INC bought a new stake in Danaher in the 1st quarter valued at $41,000. Strengthening Families & Communities LLC grew its position in Danaher by 81.4% in the 1st quarter. Strengthening Families & Communities LLC now owns 254 shares of the conglomerate’s stock worth $52,000 after purchasing an additional 114 shares during the last quarter. Finally, Saudi Central Bank acquired a new stake in Danaher in the 1st quarter worth $52,000. Institutional investors own 79.05% of the company’s stock.

Danaher Trading Down 1.0%

Shares of DHR opened at $226.24 on Friday. The company has a current ratio of 1.52, a quick ratio of 1.10 and a debt-to-equity ratio of 0.33. The stock has a market cap of $159.81 billion, a PE ratio of 46.65, a PEG ratio of 3.28 and a beta of 0.81. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $258.23. The stock has a 50 day simple moving average of $212.20 and a 200-day simple moving average of $203.16.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.17. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The firm had revenue of $6.05 billion for the quarter, compared to analysts’ expectations of $6 billion. During the same period in the prior year, the business posted $1.71 earnings per share. The business’s revenue was up 4.4% compared to the same quarter last year. On average, sell-side analysts predict that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, October 31st. Investors of record on Friday, September 26th were issued a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend was Friday, September 26th. Danaher’s dividend payout ratio (DPR) is currently 26.39%.

Insider Activity at Danaher

In other news, Director Teri List sold 3,298 shares of the firm’s stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $226.50, for a total transaction of $746,997.00. Following the completion of the sale, the director owned 20,762 shares of the company’s stock, valued at approximately $4,702,593. This trade represents a 13.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Brian W. Ellis sold 21,776 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total value of $4,773,952.48. Following the completion of the transaction, the senior vice president directly owned 14,553 shares in the company, valued at $3,190,454.19. The trade was a 59.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 30,248 shares of company stock valued at $6,609,663 in the last ninety days. Insiders own 11.10% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Danaher in a research report on Wednesday, October 8th. Wall Street Zen upgraded Danaher from a “hold” rating to a “buy” rating in a research note on Saturday, November 22nd. Redburn Partners set a $220.00 price objective on Danaher in a research report on Wednesday, October 8th. Rothschild Redb lowered Danaher from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 8th. Finally, Rothschild & Co Redburn restated a “neutral” rating and issued a $220.00 target price (down from $245.00) on shares of Danaher in a research note on Wednesday, October 8th. Eighteen analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $243.39.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.